Oct 09, 2012
By Jane Brown
An experimental Alzheimer’s drug is showing promise. Results from two studies suggest it might modestly slow mental decline, especially in patients with a mild form of the mind robbing disease.
Taken separately, the studies missed their main goals to significantly slow Alzheimer’s.
But pooled results found 34 per cent less decline in mild Alzheimer’s patients compared to those on a placebo for 18 months.
The drug is called solanezumab and is being developed by Eli Lilly & Company.